

## CURRICULUM VITAE AND BIBLIOGRAPHY

Sept. 1, 2019

### David Aguilar, MD

**PRESENT TITLE:** Associate Professor of Medicine  
Department of Medicine/Division of Cardiology  
University of Texas Medical School at Houston  
Department of Epidemiology, Human Genetics, and Environmental  
Sciences  
University of Texas School of Public at Houston

**WORK ADDRESS:** UT School of Public Health  
1200 Pressler St, E431  
Houston, TX 77030

**BIRTHDATE:** 9/11/1970

**CITIZENSHIP:** USA

#### UNDERGRADUATE EDUCATION:

B.S. Zoology, 1992 (Summa Cum Laude)  
Texas A&M University  
College Station, TX

#### GRADUATE EDUCATION:

Doctor of Medicine, 1996 (Graduation with Honors)  
Baylor College of Medicine  
Houston, TX

#### POSTGRADUATE TRAINING:

Internship, Internal Medicine, 1996-97  
Brigham and Women's Hospital  
Harvard Medical School  
Boston, MA

Residency, Internal Medicine, 1997-99  
Brigham and Women's Hospital  
Harvard Medical School, Boston, MA

Fellowship, Cardiovascular Medicine (including Level III Adult Echocardiography  
and Level II Nuclear Cardiology training), 1999-2003

Brigham and Women's Hospital  
Harvard Medical School Boston

Clinical Effective Course (Research Training), 2000  
Harvard School of Public Health  
Boston, MA

Masters of Science (Clinical Investigation), 2007-11  
Clinical Scientist Training Program  
Baylor College of Medicine  
Houston, TX

Graduate Certificate in Healthcare Management, 2012-13  
Rice University  
Houston, TX

**ACADEMIC & ADMINISTRATIVE APPOINTMENTS:**

Assistant Professor of Medicine, 2003-05  
Department of Medicine/Division of Cardiology  
University of Texas Health Science Center  
Houston, TX

Assistant Professor of Medicine, 2005-15  
Department of Medicine/Division of Cardiology  
Baylor College of Medicine  
Houston, TX

Associate Professor of Medicine (tenured), 2015-17  
Department of Medicine/Division of Cardiology  
Baylor College of Medicine  
Houston, TX

Associate Professor, 10/2017-present  
Department of Epidemiology, Human Genetics, and Environmental Sciences  
UT School of Public Health at Houston  
Houston, TX

Associate Professor of Medicine, 10/2017-present  
Department of Medicine/Cardiology  
UT McGovern Medical School at Houston  
Houston, TX

## **HOSPITAL & ADMINISTRATIVE APPOINTMENTS:**

Attending Physician, 2003-05  
Memorial Hermann Hospital-Texas Medical Center

Attending Physician, 2005-present  
CHI Baylor St. Luke's Hospital

Local Site Director for the Baylor Cardiovascular Fellowship, 2008-2014  
CHI St. Luke's Health (2008-2014)  
Baylor College of Medicine  
Houston, TX

Attending Physician, 2005-2017  
Michael E. Debakey VA Medical Center  
Houston, TX

Attending Physician, 2017-present  
Memorial Hermann Hospital-Texas Medical Center

Associate Director of the Cardiovascular Fellowship Program, 2018-2019  
Department of Medicine/Cardiology  
UT McGovern Medical School at Houston  
Houston, TX

## **OTHER PROFESSIONAL EXPERIENCE:**

Assistant Chair for Clinical Affairs, Department of Internal Medicine, Baylor College of Medicine, 2012-2017. The Assistant Chair for Clinical Affairs oversees and assists the Chair in the management of the clinical operations of the Department of Medicine Faculty Group Practice.

Vice-chair of the Subcommittee for Clinical Operations of the Department of Medicine Faculty Group Practice, Baylor College of Medicine (2012-2017)

Co-Medical Director, Transitional Care Clinic at CHI St. Luke's Health (2014-2017). The Transition Care Clinic assisted in the transition from inpatient to outpatient care in patients who have been admitted with heart failure. The primary purpose is to provide patient education and support to reduce heart failure readmission.

Cardiovascular Advisory Committee, CHI St. Luke's Health. Advisory committee regarding the strategic and operational plan of cardiovascular activities at Baylor CHI St. Luke's Health (2014-2016)

Clinical Integration Network/IT Committee, CHI St. Luke's Health (2014-2016)

Baylor Faculty Group Practice Committee, Baylor College of Medicine (2016-2017)

Faculty Group Practice Interim Medical Director, Department of Medicine, Baylor College of Medicine (10/2016-10/2017).

**LICENSURE:**

Massachusetts Medical License # 15652, 1999

Texas Medical License #L6754, 2003

**CERTIFICATION:**

American Board of Internal Medicine Certificate, Certification, 2002; Recertification, 2012

American Board of Internal Medicine, Cardiovascular Disease Certificate, Certification, 2002; Recertification, 2012

Certification in Adult Comprehensive Echocardiography, Certification 2003, Recertification 2013

American Society of Nuclear Cardiology, Certification, 2002, Recertification, 2012

**PROFESSIONAL ORGANIZATIONS:**

**LOCAL:**

American Heart Association, Houston Affiliate-Present

- American Heart Association, Houston, Co-chair, Hispanic Outreach Task Force, AHA Houston Affiliate, 2005-2007
- Health Strategies Committee, 2009
- Board of Directors, 2009-2011
- AHA Health Equity Houston Board Member. This Board addresses issues of cardiovascular health in underrepresented minority groups. 2014-2016
- Houston Heart Failure Collaboration, 2018-present

**NATIONAL:**

Fellow of the American Heart Association

- Young Clinicians and Investigator AHA National Committee Member, Council

of Clinical Cardiology. 2005-2007

- Young Clinician and Investigator Representative to AHA National Leadership Committee of the Council of Clinical Cardiology, 2005-2007
- Heart Failure and Transplantation Committee Member, Council of Clinical Cardiology, AHA. 2007-2011
- Science Strategy Task Force, AHA Council of Clinical Cardiology, 2009
- High School Minority Outreach Program, AHA Council of Clinical Cardiology. On the planning committee for a program which brings minority high school students to the AHA Scientific Sessions to learn more about opportunities in health science, 2012-current
- Planning Committee for the AHA Cardiometabolic Health and Diabetes National Summit 2017-2018
- American Heart Association/American Diabetes Association Diabetes Science Advisory Group Member, 2018-

American College of Cardiology, Member

- Population Health Policy and Health Promotion Committee, 2015-2016

## **HONORS AND AWARDS:**

Summa Cum Laude Graduate, Texas A&M University, 1992

Alpha Omega Alpha, Baylor College of Medicine, 1996

Arnold Dunne Medical Intern Award for excellence and compassionate care, Brigham and Women's Hospital, Harvard Medical School, 1997

Outstanding Commitment to Teaching Award, Section of Cardiology, Baylor College of Medicine, 2007

Outstanding Junior Faculty Award, Section of Cardiology, Baylor College of Medicine, 2008

Rising Star Clinician Award, Baylor College of Medicine, 2014

Fulbright & Jaworski L. L. P. Faculty Excellence Award in the category of Teaching and Evaluation, Baylor College of Medicine, 2014

Faculty of the Year Award. Department of Internal Medicine/Division of Cardiology. UT Health, McGovern Medical School. 2018-2019

**EDITORIAL POSITIONS:**

Associate Editor of the American Heart Journal, 2013-2017

Guest Editor, American Heart Journal, 2017-present

Editorial Board, Circulation, 2016-present

Editorial Board, American Heart Journal, 7/2016-present

**SERVICE ON NATIONAL GRANT REVIEW PANELS, STUDY SECTIONS, COMMITTEES:**

American Diabetes Association Research Grant Review Committee, 2018-current

**SERVICE ON THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON COMMITTEES:**

Faculty Search Committee-Epidemiology, Human Genetics, and Environmental Sciences, UT School of Public Health

Member of the Working Group on Public Health Services UTSPH (2019)

**SERVICE TO THE COMMUNITY:**

Manuscript Reviewer: Circulation, Journal of the American College of Cardiology, American Heart Journal, American Journal of Cardiology, Journal of Cardiac Failure, European Heart Journal, European Journal of Heart Failure, Diabetes Care, Lancet, JAMA Cardiology, Journal of the American Heart Association,

Abstract Reviewer: ACC Scientific Sessions 2007, 2010, 2013-2018, AHA Scientific Sessions 2015-2019

Minority Outreach Program for High Students Interested in Health Careers, University of Houston, 2018

Supervise Diabetes Screening (public service) in Starr County, TX, 2018-

CV Health Screening events at Baker Ripley (in conjunction with the Texas Heart Institutes Center for Women's Heart & Vascular Health, 2019-

**CURRENT TEACHING RESPONSIBILITIES:**

Rounding on the Inpatient Cardiology Consult Service, approximately 2 months per year. Medical team traditionally includes 1 cardiology fellow, 1 resident, 2 interns,

and 1 medical student. Hours rounding: Approximately 4 hours/daily. Teaching preparation- approximately 1 hour daily.

Teaching in the Echocardiography Laboratory at UT Health Science Center. Supervise 1 cardiology fellow in the analyses and reporting of transthoracic echocardiograms and performance of transesophageal echocardiograms. 2-3 full days/month.

Co-instructor CV Epidemiology (PH2740), Fall 2019, UT School of Public Health, 35 students

## **MENTORING ACTIVITIES:**

### Previous Mentees:

1. Melissa Nolan, PhD, MPH  
Current Position: Assistant Professor of Epidemiology  
University of South Carolina, Greenville, SC
2. Mohita Singh, MD  
Current Position: Cardiology Fellow  
University of Texas Southwestern, Dallas, TX

### Current Research Mentees:

1. Efstratios Kutroumpakis  
Current Position: Cardiology Fellow  
University of Texas Health Science Center, Houston, Tx  
Award "Research Fellow of Year" 2018

## **CURRENT CLINICAL SERVICE RESPONSIBILITIES:**

Attending Physician, Memorial Hermann Hospital

Attending physician in the non-invasive echocardiography lab at Memorial Hermann Hospital and University of Texas Cardiology

## **CURREN GRANT SUPPORT:**

Diabetes Progression with Metabolomic Profiling in Starr County Mexican Americans (R01)  
PI: Goo Jun, PhD  
Funding Agency: NIDDK  
Role: Co-investigator, 0.48 calendar months  
Dates: 2/28/2019-1/31/2014

Work Patterns and Diabetes Disparities (R21)  
PI: David Aguilar, MD  
Funding Agency: NIMHHD  
Role: Primary Investigator, 2.04 calendar months  
Dates 5/7/2019-5/31/2020

**PAST GRANT SUPPORT:**

Baylor Mentored Clinical Scholars Program (K12 RR17665-05 MCIA Award)  
PI: Mory Haymond, MD  
Funding Agency: NIH, Baylor College of Medicine  
Role: Provided research salary support and clinical research training as the recipient of this Mentored Research Training Grant.  
Dates: 8/01/06-07/31/2008

Cardiovascular Cell Therapy Research Network (U01 HL087318-01)  
PI: Lem Moye, MD, PhD  
Funding Agency: NHLBI  
Role: Consultant. Dr. Aguilar serves as the cardiology consultant to the coordinating center at the University of Texas School of Public Health, which is involved in the design, execution, and analysis of state of the art stem cell research in cardiovascular disease.  
Dates: 1/1/2007-present

Myocardial and Vascular Stiffness in Diabetics with Heart Failure and Normal LVEF (K01HL092585) (K01 Career Development Award)  
PI: David Aguilar, MD  
Funding Agency: NHLBI  
Role: Primary Investigator for Career Development Award examining mechanisms and treatment strategies in diabetic patients with heart failure and normal ejection  
Dates: 8/15/2008-7/31/2012  
Annual Direct Cost: \$127,500; Total Direct Cost: \$550,800

GWAS for Sleep Apnea and Endothelial Function Among Mexican Americans (R01HL102830)  
PI: Craig L. Hanis, PhD  
Funding Agency: NHLBI  
Role: PI of a subcontract. Responsibilities (subcontract to Baylor) include protocol development and interpretation and analyses of echocardiographic data and interpretation and analysis of vascular studies (endothelial function, central blood pressure, pulse wave velocity). The primary aim is to examine genetic



underpinnings of sleep apnea, endothelial function, and arterial stiffness in a cohort of approximately 1,200 Mexican-American Individuals.

Dates: 7/1/2010-6/30/2015

Annual Direct Cost: \$685,866; Total Direct Costs: \$2,781,305

Baylor Subcontact: Annual Direct Cost: \$42,857; Total Direct Costs: \$202,697

Evaluation of Lixisenatide in Acute Coronary Syndrome (ELIXA)

Funding Agency: Sanofi-Aventis

Role: Dr. Aguilar was the US National Coordinator for this phase III industry-sponsored clinical trial of 6,000 individuals evaluating the role of lixisenatide (GLP-1 agonist) in the reduction of cardiovascular disease in patients with type 2 DM and acute coronary syndrome. Dr. Aguilar oversees all aspects of clinical trial in the United States.

Dates: 7/2010-6/2015

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL). A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly in Patients With Type 2 Diabetes Mellitus

Funding Agency: Bristol-Myers Squibb and Astra-Zeneca

Role: Dr. Aguilar was the US National Coordinator for this phase III industry-sponsored clinical trial of 14,000 individuals evaluating the role of exenatide-LR (GLP-1 agonist) in the reduction of cardiovascular disease in patients with type 2 DM who are high risk for CVD. Dr. Aguilar oversees all aspects of clinical trial in the United States.

Dates: 6/2010- 6/2017

Cardiac Manifestations of Chagas Disease in Trypanosoma Cruzi Positive Blood Donors, Houston, TX

PI: Melissa Nolan Garcia

Funding Agency: Baylor College of Medicine Cardiovascular Research Institute

Role: Co-investigator. The primary aim of this pilot study was to evaluate the cardiovascular status among blood donors who test positive for T. Cruzi.

Dates: 1/2013-1/2014

Prevalence of Chagas in Patients with Dilated Cardiomyopathy (R21AI114877)

PI: Kristy Murray, PhD

Funding Agency: National Institute of Allergy and Infectious Diseases

Role: Co-investigator. The primary aim of study is determine the prevalence of Chagas disease in non-ischemic cardiomyopathy patients in Houston.

Dates: 6/2015-6/2017

Annual Direct Cost: \$150,000; Total Direct Costs: \$239,400

## **PUBLICATIONS:**

## **A. Refereed Original Articles in Journals**

1. Aguilar D, Goldhaber SZ. Clinical uses of low molecular weight heparins. *Chest* 1999; 115(5):1418-23.
2. Aguilar D, Skali H, Moyé LA, Lewis EF, Gaziano JM, Rutherford JD, Hartley LH, Randall OS, Geltman EM, Lamas GA, Rouleau JL, Pfeffer MA, Solomon SD. Alcohol Consumption and Prognosis in Patients with Left Ventricular Systolic Dysfunction After a Myocardial Infarction. *Journal of American College of Cardiology* 2004; 43:2015-21.
3. Aguilar D, Goldhaber SZ, Gans DJ, Levey AS, Porush JG, Lewis JB, Rouleau JL, Berl T, Lewis EJ, Pfeffer MA, and the Collaborative Study Group. Clinically Unrecognized Q-Wave Myocardial Infarction in Patients with Diabetes Mellitus, Systemic Hypertension, and Nephropathy. *American Journal of Cardiology* 2004; 94:337-39.
4. Aguilar D, Solomon SD, Køber L, Rouleau JL, M.D., Skali H, McMurray JJ, Francis GS, Henis M, O'Connor CM, Diaz R, Belenkov YN, Varshavsky S, M.D., Leimberger JD, Velazquez EJ, Califf RM, Pfeffer MA. Newly Diagnosed and Previously Known Diabetes Mellitus and 1-year Outcomes of Acute Myocardial Infarction: the VALIANT Trial. *Circulation* 2004; 1572-78.
5. Aguilar D and Solomon SD. Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers and the Incidence of New-Onset Diabetes: An Emerging Theme. *Drugs* 2006; 66(9):1169-77.
6. Aguilar D, Fisher MR, O'Connor CM, Dunne MW, Muhlestein JB, Yao L, Gupta S, Benner RJ, PhD, Cook TD, Pfeffer MA. Metabolic Syndrome, Inflammation, and Prognosis in Individuals with Known Coronary Artery Disease. *American Heart Journal* 2006; 15(2): 298-304.
7. Leichman JG, Aguilar D, King TM, Vlada A, Reyes M, and Taegtmeyer H. An Association of Plasma Free Fatty Acids and Left Ventricular Diastolic Function in Patients with Clinically Severe Obesity. *American Journal of Clinical Nutrition* 2006; 84(2): 336-41.
8. Leichman J, Aguilar D, King TM, Mehta S, Scarborough T, Wilson EB, Taegtmeyer H. Improvements in Systemic Metabolism, Anthropometrics, and Left Ventricular Geometry Three Months after Bariatric Surgery. *Surgery for Obesity and Related Diseases* 2006. *Surgery for Obesity and Related Diseases* 2006; 2(6):592-9.
9. Leichman JG, Lavis VR, Aguilar D, Wilson CR, Taegtmeyer H. The metabolic syndrome and the heart—a considered opinion. *Clinical Research in Cardiology* 2006; 95 (supplement 1):134-141

10. Estep JD and Aguilar D. Diabetes and Heart Failure in the Post-Myocardial Infarction Patient. *Current Heart Failure Reports* 2006; 3:164-169.
11. Aguilar D, Bozkurt B, Pritchett A, Petersen NJ, Deswal A. The Impact of Thiazolidinedione Use on Outcomes in Ambulatory Patients with Diabetes Mellitus and Heart Failure. *Journal of American College of Cardiology* 2007; 7(50):32-36.
12. MacDonald MR, Petrie M, Hawkins N, Petrie J, Fisher M, McKelvie R, Aguilar D, Krum H, McMurray JJ. Diabetes, Left Ventricular Systolic Dysfunction, and Chronic Heart Failure. *European Heart Journal Eur Heart J* 2008; 29(10): 1224-40.
13. Hassan SA, Deswal A, Bozkurt B, Aguilar D, Mann DL, Pritchett AM. The Metabolic Syndrome and Mortality in an Ethnically Diverse Heart Failure Population. *Journal of Cardiac Failure* 2008; 14(7):590-5.
14. Leichman JG, Wilson EB, Scarborough T, Aguilar D, Miller CC, Yu S, MD, Algahim MF, Reyes M, Moody FG, Taegtmeier H. Dramatic Reversal of Derangements in Muscle Metabolism and Diastolic Left Ventricular Function After Bariatric Surgery. *The American Journal of Medicine* 2008; 121(11):966-73.
15. Aguilar D. Management of Type 2 Diabetes in Patients with Heart Failure. *Current Treatment Options in Cardiovascular Medicine* 2008; 10(6): 465-75.
16. Aguilar D, Hallman DM, Piller LB, Klein, BE, Klein R, Devereux RB, Arnett DK, Gonzalez VH, Hanis CL. Adverse Association between Diabetic Retinopathy and Abnormal Cardiac Structure and Function. *American Heart Journal* 2009; 157(3): 563-8.
17. Dhaliwal AS, Deswal A, Pritchett A, Aguilar D, Kar B, Soucek J, Bozkurt B. Reduction in BNP Levels with Treatment of Decompensated Heart Failure and Future Clinical Events. *Journal of Cardiac Failure* 2009; 15(4):293-9.
18. Dhaliwal A, Habib G, Deswal A, Verduzco M, Soucek J, Ramasubbu, K , Aguilar D, Ma T, Jneid H, Bozkurt B. Impact of Alpha 1-Adrenergic Antagonist Use for Benign Prostatic Hypertrophy on Outcomes in Patients with Heart Failure. *Am J Cardiol* 2009; 104(2):270-5.
19. Aguilar D, Bozkurt B, Ramasubbu K, Deswal A. Relationship of Hemoglobin A1C and Mortality in Heart Failure Patients with Diabetes. *Journal of the American College of Cardiology* 2009; 54(5):422-8.
20. Aguilar D, Deswal A, Ramassubu K, Mann DL, Bozkurt B. Comparison of Patients with Heart Failure and Preserved Left Ventricular Ejection Fraction Among Those With versus Without Diabetes Mellitus. *American Journal of Cardiology* 2010; 105(3):373-7.

21. Ramasubbu K, Deswal A, Herdejurgan C, Aguilar, D, Frost AE. A prospective echocardiographic evaluation of pulmonary hypertension in chronic hemodialysis patients in the United States: prevalence and clinical significance. *International Journal of General Medicine* 2010; 3:279-286.
22. Aguilar D, Chan W, Bozkurt B, Ramasubbu K, Deswal A. Metformin Use and Mortality in Ambulatory Patients with Diabetes and Heart Failure. *Circulation Heart Failure* 2011; 4(1):53-8.
23. Addison D and Aguilar D. Diabetes and Cardiovascular Disease: The Potential Benefit of Incretin Based Therapies. *Current Atherosclerosis Reports* 2011; 161(3):115-22.
24. Ather S, Chan W, Chillar A, Aguilar D, Pritchett AM, Ramasubbu K, Wehrens XH, Deswal A, Bozkurt B. Association of Systolic Blood Pressure with Mortality in Patients with Heart Failure with Reduced Ejection Fraction: A Complex Relationship. *American Heart Journal* 2011; 161(3): 567-73.
25. Ye Y, Perez-Polo JR, Aguilar D, Birnbaum Y. The potential effects of anti-diabetic medications on myocardial ischemia-reperfusion injury. *Basic Res Cardiol* 2011; 106(6): 925-52.
26. Traverse JH, Henry TD, Ellis SG, Pepine CJ, Willerson JT, Zhao DX, Forder JR, Byrne BJ, Hatzopoulos AK, Penn MS, Perin EC, Baran KW, Chambers J, Lambert C, Raveendran G, Simon DI, Vaughan DE, Simpson LM, Gee AP, Taylor DA, Cogle CR, Thomas JD, Silva GV, Jorgenson BC, Olson RE, Bowman S, Francescon J, Geither C, Handberg E, Smith DX, Baraniuk S, Piller LB, Loghin C, Aguilar D, Richman S, Zierold C, Bettencourt J, Sayre SL, Vojvodic RW, Skarlatos SI, Gordon DJ, Ebert RF, Kwak M, Moyé LA, Simari RD; for the Cardiovascular Cell Therapy Research Network (CCTRN). Effect of Intracoronary Delivery of Autologous Bone Marrow Mononuclear Cells 2 to 3 Weeks Following Acute Myocardial Infarction on Left Ventricular Function: The LateTIME Randomized Trial. *JAMA* 2011; 306(19): 2110-9.
27. Ather S, Hira RS, MD1, Shenoy M, Fatemi O, Deswal A, Aguilar D, Ramasubbu K, Bolos M, Chan W, Bozkurt B. Recurrent Low-Level Troponin I Elevation is a Worse Prognostic Indicator than Occasional Injury Pattern in Patients Hospitalized with Heart Failure. *International Journal of Cardiology* 2011.
28. Ather S, Chan W, Bozkurt B, Aguilar D, Ramasubbu K, Zachariah AA, Wehrens X, Deswal A. Impact of Non-Cardiac Comorbidities on Morbidity and Mortality in Heart Failure with Preserved versus Reduced Ejection Fraction. *Journal of the American College of Cardiology* 2012; 59(11): 998-1005.
29. Perin EC, Willerson JT, Pepine CJ, Henry TD, Ellis SG, Zhao DX, Silva GV, Lai D, Thomas JD, Kronenberg MW, Martin AD, Anderson RD, Traverse JH, Penn MS, Anwaruddin S, Hatzopoulos AK, Gee AP, Taylor DA, Cogle CR, Smith D, Westbrook L, Chen J, Handberg E, Olson RE, Geither C, Bowman S, Francescon J, Baraniuk S,

- Piller LB, Simpson LM, Loghin C, Aguilar D, Richman S, Zierold C, Bettencourt J, Sayre SL, Vojvodic RW, Skarlatos SI, Gordon DJ, Ebert RF, Kwak M, Moyé LA, Simari RD; for the Cardiovascular Cell Therapy Research Network (CCTRN). Effect of Transendocardial Delivery of Autologous Bone Marrow Mononuclear Cells on Functional Capacity, Left Ventricular Function, and Perfusion in Chronic Heart Failure. *JAMA* 2012; 307(16):1717-26
30. Ather S, Bavishi C, McCauley MD, Dhaliwal A, Deswal A, Johnson S, Chan W, Aguilar D, Pritchett AM, Ramasubbu K, Wehrens XH, Bozkurt B. Worsening Renal Function is not Associated with Response to Treatment in Acute Heart Failure. *In J Cardiol* 2012;
  31. Ramasubbu, K, Deswal A, Chan, W, Aguilar D, Bozkurt, B. Echocardiographic Changes During Treatment of Acute Decompensated Heart Failure: Insights From the ESCAPE Trial. *J Card Fail* 2012; 18(10) 792-8.
  32. Nasir S and Aguilar D. Congestive Heart Failure and Diabetes Mellitus: Balancing Glycemic Control with Heart Failure Improvement. *Am J Cardiol* 2012; 110 (9 Supl):50B-7B.
  33. Pritchett AM, Deswal A, Aguilar D, Foreyt JP, Chan W, Mann DL, Ballantyne C, Bozkurt B. Lifestyle Modification with Diet and Exercise in Obese Patients with Heart Failure-A Pilot Study. *J Obes Weight Loss Ther* 2012; 2(2):1-8.
  34. Traverse JH, Henry TD, Pepine CJ, Willerson JT, Zhao DX, Ellis SG, Forder JR, Anderson RD, Hatzopoulos AK, Penn MS, Perin EC, Chambers J, Baran KW, Raveendran G, Lambert C, Lerman A, Simon DI, Vaughan DE, Lai D, Gee AP, Taylor DA, Cogle CR, Thomas JD, Olson RE, Bowman S, Francescon J, Geither C, Handberg E, Kappenman C, Westbrook L, Piller LB, Simpson LM, Baraniuk S, Loghin C, Aguilar D, Richman S, Zierold C, Spoon DB, Bettencourt J, Sayre SL, Vojvodic RW, Skarlatos SI, Gordon DJ, Ebert RF, Kwak M, Moyé LA, Simari RD; for the Cardiovascular Cell Therapy Research Network (CCTRN). Effect of the Use and Timing of Bone Marrow Mononuclear Cell Delivery on Left Ventricular Function After Acute Myocardial Infarction: The TIME Randomized Trial. *JAMA* 2012; 308 (22):2380-0
  35. Zheng, Y, Yu, B, Alexander, D, Manolio TA, Aguilar D, Coresh J, Heiss G, Boerwinkle E, Nettleton JA. Associations between Metabolomic Compounds and Incident Heart Failure among African Americans: the Atherosclerosis Risk in Communities (ARIC) Study. *American Journal of Epidemiology* 2013; 178(4):534-42.
  36. Huang HD, Alam M, Hamzeh I, Virani S, Deswal A, Aguilar D, Rogers P, Kougas P, Birnbaum Y, Paniagua D, Kar B, Ballantyne C, Bozkurt B, Jneid H. Patients with severe chronic kidney disease benefit from early revascularization after acute coronary syndrome. *Int J Cardiol* 2013; 168(4)3741-6.
  37. Nambi V, Liu X, Chambless LE, de Lemos JA, Virani SS, Agarwal S, Boerwinkle E, Hoogeveen RC, Aguilar D, Astor BC, Srinivas PR, Deswal A, Mosley TH, Coresh J,

Folsom AR, Heiss G, Ballantyne CM. Troponin T and NT-Pro B-Type Natriuretic Peptide: A Biomarker Approach to Predict Heart Failure Risk— the Atherosclerosis Risk in Communities Study. *Clinical Chemistry* 2013; 59(12):1802-10.

38. Vardeny O, Gupta DK, MD; Claggett B, Burke S, Shah A, Loehr L, Rasmussen-Torvik L, Selvin E, Chang PP, Aguilar D, SD, MD Insulin Resistance and Incident Heart Failure: The Atherosclerosis Risk in Communities Study. *JACC HF*; 2013; 1(6):531-536
39. Schurmann P, Basra S, Awar OG, Aguilar D, Arya B, Dragan E, Hutton GJ, Birnbaum Y. Abnormal rhythms in patients without known cardiac disease after a first dose of fingolimod. *Mult Scler Relat Disor*. 2014; 3(3):408-12.
40. Gupta DK, Skali H, Claggett B, Kasabov R, Cheng S, Shah AM, Loehr LR, Heiss G, Nambi V, Aguilar D, Wruck LM, Matsushita K, Folsom AR, Rosamond WD, Solomon SD. Heart Failure Risk Across the Spectrum of Ankle Brachial Index: The ARIC Study (Atherosclerosis Risk in Communities). *JACC Heart Fail*. 2014; Oct;2(5):447-54.
41. Cardoso RN, Macedo FY, Garcia MN, Garcia DC, Benjo AM, Aguilar D, Jneid H, Bozkurt B. Chagas' cardiomyopathy is associated with higher incidence of stroke: a meta-analysis of observational studies. *J Card Fail*. 2014; 931-8.
42. Garcia MN, Aguilar D, Gorchakov R, Rossmann SN, Montgomery SP, Rivera H, Woc-Colburn L, Hotez PJ, Murray KO. Evidence of Autochthonous Chagas Disease in Southeastern Texas. *Am J Trop Med Hyg*. 2015; 92:325-30.
43. Garcia MN, Murray KO, Hotez PJ, Rossman SN, Gorchakov R, Ontiveros A, Woc-Colburn L, Bottazzi ME, Rhodes CE, Ballantyne CM, Aguilar D. Development of Chagas Cardiac Manifestations Among Texas Blood Donors. *Am J Cardiol* 2015; 115(1):113-117.
44. Gonçalves A, Claggett B, Jhund PS, Rosamond W, Deswal A, Aguilar D, Shah AM, Cheng S, Solomon SD. Alcohol Consumption and risk of heart failure: the Atherosclerosis Risk in Communities Study. *Eur Heart J* 2015; 36(15):939-45.
45. Bentley-Lewis R, Aguilar D, Riddle MC, Claggett B, Diaz R, Dickstein K, Gerstein HC, Johnston P, Kober LV, Lawson F, Lewis E, Maggioni AP, McMurray JJV, Ping L, Probstfield JL, Solomon SD, Tardiff JC, Wu Y, Pfeffer MA. Rational, design, and baseline characteristics in Evaluation of Lixisenatide in Acute Coronary Syndrome, a long-term cardiovascular endpoint trial of lixisenatide versus placebo. *American Heart Journal* 2015; 169(5): 631-638.
46. Skali H, Shah A, Gupta DK, Cheng S, Claggett B, Bello N, Aguilar D, Vardeny O, Matsushita K, Selvin E, Solomon S. Cardiac structure and function across the glycemic spectrum in elderly subjects without prevalent heart disease: the Atherosclerosis Risk in the Community (ARIC) study. *Circulation: Heart Failure* 2015; 8(3):448-54.

47. Meyer ML, Tanaka H, Palta P, Cheng S, Gouskova N, Aguilar D, Heiss G. Correlates of Segmental Pulse Wave Velocity in Older Adults: The Atherosclerosis Risk in Communities (ARIC) study. *Am J Hypertension* 2016; 29(1):114-22.
48. Garcia MN, Woc-Colburn L, Aguilar D, Hotez PJ, Murray KO. Historical Perspectives on the Epidemiology of Human Chagas Disease in Texas and Recommendations for Enhanced Understanding of Clinical Chagas Disease in the Southern United States. *PLoS Negl Trop Dis* 2015; 9(11)
49. Brown EL, Below JE, Fischer RS, Essigmann HT, Hu H, Huff C, Robinson DA, Petty LE, Aguilar D, Bell GI, Hanis CL. Genome-Wide Association Study of *Staphylococcus aureus* Carriage in a Community-Based Sample of Mexican-Americans in Starr County, Texas. *PLoS One*. 2015 Nov 16;10
50. Camplain R, Meyer ML, Tanaka H, Palta P, Agarwal SK, Aguilar D, Butler KR, Heiss G. Smoking Behaviors and Arterial Stiffness Measured by Pulse Wave Velocity in Older Adults: The Atherosclerosis Risk in Communities (ARIC) Study. *Am J Hypertens* 2015.
51. Gori M, Gupta DK, Claggett B, Selvin E, Folsom AR, Matsushita K, Bello NA, Cheng S, Shah A, Skali H, Vardeny O, Ni H, Ballantyne CM, Astor BC, Klein BE, Aguilar D, Solomon SD. Natriuretic Peptide and High-Sensitivity Troponin for Cardiovascular Risk Prediction in Diabetes: The Atherosclerosis Risk in Communities (ARIC) Study. *Diabetes Care* 2016; 39(5):677-85
52. Smith JG, Felix JF, Morrison AC, Kalogeropoulos A, Trompet S, Wilk JB, Gidlöf O, Wang X, Morley M, Mendelson M, Joehanes R, Ligthart S, Shan X, Bis JC, Wang YA, Sjögren M, Ngwa J, Brandimarto J, Stott DJ, Aguilar D, Rice KM, Sesso HD, Demissie S, Buckley BM, Taylor KD, Ford I, Yao C, Liu C; CHARGE-SCD consortium; EchoGen consortium; QT-IGC consortium; CHARGE-QRS consortium, Sotoodehnia N, van der Harst P, Stricker BH, Kritchevsky SB, Liu Y, Gaziano JM, Hofman A, Moravec CS, Uitterlinden AG, Kellis M, van Meurs JB, Margulies KB, Dehghan A, Levy D, Olde B, Psaty BM, Cupples LA, Jukema JW, Djousse L, Franco OH, Boerwinkle E, Boyer LA, Newton-Cheh C, Butler J, Vasan RS, Cappola TP, Smith NL. Discovery of Genetic Variation on Chromosome 5q22 Associated with Mortality in Heart Failure. *PLoS Genet*. 2016
53. Hanis CL, Redline S, Cade BE, Bell GI, Cox NJ, Below JE, Brown EL, Aguilar D. Beyond Type 2 Diabetes, Obesity and Hypertension: An Axis Including Sleep Apnea, Left Ventricular Hypertrophy, Endothelial Dysfunction, and Aortic Stiffness among Mexican Americans in Starr County, Texas. *Cardiovascular Diabetology* 2016; 8;15(1):86
54. Bello NA, Cheng S, Claggett B, Shah AM, Ndumele CE, Roca GQ, Santos AB, Gupta D, Vardeny O, Aguilar D, Folsom AR, Butler KR, Kitzman DW, Coresh J, Solomon SD. Association of Weight and Body Composition on Cardiac Structure and Function in the ARIC Study (Atherosclerosis Risk in Communities). *Circ Heart Fail*. 2016 Aug;9(8)

55. Fuchsberger C, Flannick J,...Aguilar D.... McCarthy MI. The genetic architecture of type 2 diabetes. *Nature*. 2016 Aug 4;536(7614):41-7.
56. Bozkurt B, Aguilar D, Deswal A, Dunbar SB, Francis GS, Horwich T, Jessup M, Kosiborod M, Pritchett AM, Ramasubbu K, Rosendorff C, Yancy C; American Heart Association Heart Failure and Transplantation Committee of the Council on Clinical Cardiology; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular and Stroke Nursing; Council on Hypertension; and Council on Quality and Outcomes Research. Contributory Risk and Management of Comorbidities of Hypertension, Obesity, Diabetes Mellitus, Hyperlipidemia, and Metabolic Syndrome in Chronic Heart Failure: A Scientific Statement From the American Heart Association. *Circulation*. 2016 Dec 6;134(23):e535-e578
57. Blangero J, Teslovich TM, Sim X, Almeida MA, Jun G, Dyer TD, Johnson M, Peralta JM, Manning A, Wood AR, Fuchsberger C, Kent JW Jr, Aguilar D, Below JE, Farook VS, Arya R, Fowler S, Blackwell TW, Puppala S, Kumar S, Glahn DC, Moses EK, Curran JE, Thameem F, Jenkinson CP, DeFronzo RA, Lehman DM, Hanis C, Abecasis G, Boehnke M, Göring H, Duggirala R, Almasy L; T2D-GENES Consortium. Omics-squared: human genomic, transcriptomic and phenotypic data for genetic analysis workshop 19. *BMC Proc*. 2016 Oct 18;10 (Suppl 7):71-77
58. Gunter SM, Murray KO, Gorchakov R, Beddard R, Rossmann SN, Montgomery SP, Rivera H, Brown EL, Aguilar D, Widman LE, Garcia MN. Likely Autochthonous Transmission of *Trypanosoma cruzi* to Humans, South Central Texas, USA. *Emerg Infect Dis*. 2017 Mar;23(3):500-503.
59. Manning A, Highland HM, Gasser J ...Aguilar D...Lindgren, CM. A low-frequency inactivating Akt2 variant enriched in the Finnish population is associated with fasting insulin levels and type 2 diabetes risk. *Diabetes* 2017; 66(7):2019-2032.
60. Tajik AA, Dobre D, Aguilar D, Kjekshus J, Zannad F, Dickstein K; High-Risk MI Database Scientific Committee. A history of diabetes predicts outcomes following myocardial infarction: an analysis of the 28 771 patients in the High-Risk MI Database. *Eur J Heart Fail* 2017;19(5):635-42.
61. Fashanu OE, Heckbert SR, Aguilar, D, Ballantyne CM, Basu S, Hoogeveen R, Cushman M, Folsom AR. Galectin-3 and venous thromboembolism incidence: The Atherosclerosis Risk in Communities (ARIC) study. *Research and Practice in Thrombosis and Haemostasis* 2017; 1(2):223-230.
62. Fashanu OE, Norby FL, Aguilar D, Ballantyne CM, Hoogeveen RC, Chen LY, Soliman EZ, Alonso A, Folsom AR. Galectin-3 and incidence of atrial fibrillation: The Atherosclerosis Risk in Communities (ARIC) study. *Am Heart J* 2017; 192:19-25.



63. Flannick J, Fuchsberger C, Mahajan A...Aguilar D, .... McCarthy MI. Sequence data and association statistics from 12,940 type 2 diabetes cases and controls. *Sci Data*. 2017; 19;4:170-179
64. Trang A and Aguilar D. Treating Disease Mechanisms in Patients with Heart Failure and Diabetes Mellitus. *Curr Heart Fail Rep* 2017; 14(6): 445-453.
65. Rebholz CM, Selvin E, Liang M, Ballantyne CM, Hoogeveen RC, Aguilar D, McEvoy JW, Grams ME, Coresh J. Plasma galectin-3 levels and risk of chronic kidney disease. *Kidney Int* 2018;93(1):252-259.
66. Vazir R, Claggett B, Cheng S, Skali H, Shah A, Aguilar D, Ballantyne CM, Vardeny O, Solomon SD. Association of Resting Heart Rate and Temporal Changes in Heart Rate with Outcomes in Participants in the Atherosclerosis Risk in Communities Study. *JAMA Cardiol* 2018; 3(3): 200-206
67. Oyenuga A, Folsom AR, Fashanu O, Aguilar D, Ballantyne CM. Plasma Galectin-3 and Sonographic Measures of Carotid Atherosclerosis in the Atherosclerosis Risk in Communities Study. *Angiology* 2019; 70(1):47-55
68. Tanaka H, Palta P, Folsom AR, Meyer ML, Matsushita K, Evenson KR, Aguilar D, Heiss G. Habitual physical activity and central artery stiffening in older adults: the Atherosclerosis Risk in Communities study. *J Hyperten* 2018; 36(9):1889-1894.
69. Mentz R, Thompson VP, Aguilar D, Choi J, Gustavson SM, Iqbal N, Kong APS, Ohman P, Sattar N, Scott RS, Wong YW, Holman RR, Hernandez AF. Effects of once-weekly exenatide on clinical outcomes in patients with preexisting cardiovascular disease: a prespecified analysis from EXSCEL. *Circulation* 2018; 138(22):2576-2578.
70. Nolan MS, Hanis CL, Aguilar D, Brown EL, Gunter SM, Ronca SE, and Murray KO. Continuing evidence of human Chagas disease along the Texas-Mexico border. *PLOS Neglected Tropical Diseases* 2018; 12(11):e0006899.
71. Rossello, X, Ferreira JP, McMurray JJV, Aguilar D, Pfeffer MA, Pitt B, Dickstein K, Gierd N, Rossignol P, Zannad F. Impact of insulin-treated diabetes on cardiovascular outcomes following high risk myocardial infarction. *European Heart Journal: Acute Cardiovascular Care* 2019;8(3):231-241.
72. Petty LE, Highland HM, Gamazon ER, Hu H, Karhade M, Chen H, de Vries PS, Grove ML, Aguilar D, Bell GI, Huff CD, Hanis CL, Doddapaneni HV, Munzy DM, Gibbs RA, Ma J, Parra EJ, Cruz M, Valladares-Salgado A, Arking DE, Barbeira A, Im HK, Morrison AC, Boerwinkle E, Below JE. Functionally oriented analysis of cardiometabolic traits in a trans-ethnic sample. *Human Molecular Genetics* 2019; 28(7): 1212-1224

73. Singh M, Hanis CL, Redline S, Ballantyne CM, Hamzeh I, Aguilar D. Sleep apnea and galectin-3: possible sex specific relationship. *Sleep and Breathing* 2019; epub
74. Trang A, Kampangkaew J, Fernandes R, Tiwana J, Misra A, Hamzeh I, Blaustein A, Aguilar D, Shah T, Ballantyne CM, Quinones Q, Nagueh SF, Dokanish H, Virani SS, Deswal A, Kirkpatrick JN, Nambi V. Understanding by General Providers of the Echocardiogram Report. *American Journal of Cardiology* 2019; 124(2);296-302
75. Sonawane K, Zhu Y, Balkrishnan R, Suk R, Sharrief A, Deshmukh AA, Aguilar D. Antihypertensive drug use and blood pressure control among stroke survivors in the United States: NHANES 2003-2014. *J Clin Hypertens* 2019; 766-773.
76. Yazadani A, Yazdani A, Medex-Giraldez R, Aguilar D, Satore L. A multi-trait approach identified genetic variants including a rare mutation in RGS3 with impact on abnormalities of cardiac structure and function. *Sci Report* 2019; 9(1) 5845.
77. Dunlay SM, Givertz MM, Aguilar D, Allen LA, Chan M, Desai AS, Deswal A, Dickson VV, Kosiborod MN, Lekavich CL, McCoy RG, Mentz RJ, Piña IL; American Heart Association Heart Failure and Transplantation Committee of the Council on Clinical Cardiology; Council on Cardiovascular and Stroke Nursing; and the Heart Failure Society of America. Type 2 diabetes mellitus and heart failure: A scientific statement from the American Heart Association and the Heart Failure Society of America. *Circulation* 2019; 140 (7): e294-324
78. Dunlay SM, Givertz MM, Aguilar D, Allen LA, Chan M, Desai AS, Deswal A, Dickson VV, Kosiborod MN, Lekavich CL, McCoy RG, Mentz RJ, Piña IL; American Heart Association Heart Failure and Transplantation Committee of the Council on Clinical Cardiology; Council on Cardiovascular and Stroke Nursing; and the Heart Failure Society of America. Type 2 diabetes mellitus and heart failure: A scientific statement from the American Heart Association and the Heart Failure Society of America. *J Card Fail* 2019; 25(8):584-619.

## **B. Invited Articles in Journals**

1. Aguilar D. The Clinically Unrecognized Q-wave Myocardial Infarction: What Does it Mean, and What Should We Do? *American Heart Journal* 2006; 151 (4): 768-70.
2. Aguilar D. Glycated Hemoglobin as a Prognostic Risk Marker in Non-Diabetic Patients following Acute Myocardial Infarction-What Now? *Circulation* 2011; 124(6):666-8.
3. Aguilar D. Diabetes and Heart Failure: Time to Pay Attention. *American Heart Journal* 2011; 162(5): 795-7.
4. Aguilar D. Diabetes, Heart Failure, and Chronic Kidney Disease: A Clinical Conundrum. *Circulation Heart Failure* 2016; 9(7).

5. Aguilar D. Improving Outcomes in Patients with Diabetes Mellitus. Journal of the American Heart Association 2019; 18(4).

### **C. Chapters**

1. Aguilar D, Bulwer BE. Echocardiography in Pulmonary Embolism and Secondary Pulmonary Hypertension. In: Solomon SD, ed. Essential Echocardiography: A Practical Casebook with DVD. Humana Press, New Jersey. 2006.
2. Aguilar D. Cardiac Tumors. ACC SAP-8. 2012
3. Aguilar D and Levine GN. Cardiac Tumors. Cardiac Secrets, 4<sup>th</sup> edition; Saunders Publishers, 2014.
4. Aguilar D. "Epidemiology of Diabetes and Heart Failure." Diabetes in Cardiovascular Disease: A Companion to Braunwald's Heart Disease. Elsevier Publisher, 2014
5. Aguilar D. Cardiac Tumors. ACC SAP-9. 2016
6. Aguilar D and Levine GN. Cardiac Tumors. Cardiac Secrets, 5<sup>th</sup> edition; Saunders Publishers, 2017.
7. Aguilar D. Cardiac Tumors, ACC-SAP 2019

### **D. Other Professional Communications**

#### **D.1. Presentations**

##### **Local**

1. "Clinical Pathologic Conference"  
University of Texas Health Science Center-Internal Medicine Grand Rounds  
Houston, TX; Mar 1, 2004
2. "Interesting Echo Cases"  
Texas Heart Institute Echo Conference  
Houston, TX; June 13, 2006
3. "Board Review: Echocardiography"  
Texas Heart Institute Fellow Lecture  
Houston, TX; December 11, 2006
4. "Diabetes and Heart Failure: A Dangerous Intersection"

Section of Cardiology Research Conference, Baylor College of Medicine  
Houston, TX: February 12, 2007

5. "Echocardiography and Clinical Management: Interesting Cases"  
Texas Heart Institute Echo Conference  
Houston, TX; May 8, 2007
6. "Chest Pain: The Clinical Science and Therapeutics of Atherosclerotic Coronary Artery Disease"  
Mechanisms & Management of Diseases, Baylor Medical Students  
Houston, TX; September 6, 2007
7. "Adverse Association of Diabetes and Heart Failure and Impact of TZD Therapy"  
Endocrinology Research Conference  
Houston, TX; March 31, 2008
8. "Diabetes and Cardiovascular Disease: A Dangerous Intersection"  
University of Texas School of Public Health  
Biologic Basis of Emerging Disease Course  
Houston, TX; April 2, 2008
9. "Diabetes and Heart Failure with Normal Ejection Fraction"  
Section of Cardiology Research Conference, Baylor College of Medicine  
Houston, TX; April 21, 2008
10. "Diabetes Mellitus and SPECT Imaging"  
Baylor Cardiology Fellows Educational Conference  
Houston, TX; April 21, 2008
11. "Preoperative Evaluation using Myocardial Perfusion Imaging"  
Baylor Cardiology Fellows Educational Conference  
Houston, TX; January 15, 2009
12. "Does Glycemic Control Matter in Cardiovascular Risk Reduction?"  
Section of Cardiology Research Conference, Baylor College of Medicine  
Houston, TX; February 10, 2009
13. "Diabetes and Cardiovascular Disease"  
University of Texas School of Public Health-Houston  
Biologic Basis of Emerging Disease Course  
Houston, TX; April 8, 2009
14. "Diabetes Mellitus and SPECT Imaging"  
Baylor Cardiology Fellows Educational Conference  
Houston, TX; November 2009

15. "Potential Role of Incretin-Based Therapies in Prevention and Treatment of Cardiovascular Disease"  
Section of Cardiology Research Conference, Baylor College of Medicine  
Houston, TX; Feb 28, 2011
16. "Diabetes Mellitus and SPECT Imaging"  
Baylor Cardiology Fellows Educational Conference  
Houston, TX; March 21, 2011
17. "Cardiac Masses"  
Baylor Cardiology Fellows Educational Conference  
Houston, TX; December 14, 2011
18. "Metformin for the Treatment of Heart Failure"  
Section of Cardiology Research Conference, Baylor College of Medicine  
Houston, TX; February 13, 2012
19. "Diabetes Mellitus and SPECT Imaging"  
Baylor Cardiology Fellows Educational Conference  
Houston, TX; December 19, 2012
20. "Chagas Cardiomyopathy: The Hidden Endemic"  
Texas Children's Research Seminar  
Houston, TX; January 23, 2014
21. "Starr County Research: Diabetes, Arterial Stiffness, and Much More"  
Section of Cardiology Research Conference  
Houston, Tx, April 20, 2015
22. "Stable Ischemic Heart Disease"  
Baylor Cardiology Fellows Educational Conference  
Houston, TX, October 2015, September 2016, September 2017
23. "Diabetes and Cardiovascular Disease"  
UT Cardiology Fellows  
Houston, Tx Feb 2018

## **National**

1. "The Diabetic and the Myocardial Infarction"  
Grand Rounds, UT Houston Health Science Center  
Houston, TX; February 27, 2003
2. "Hypertension to Heart Failure: The CV Continuum"  
Challenges of Treating Hypertension in the Latino Population  
Novartis Regional Advisory Board Meeting

Dallas, TX; October 23, 2004

3. "Diabetes and Heart Failure: A Dangerous Intersection"  
Endocrinology Grand Rounds, Baylor College of Medicine  
Houston, TX; May 11, 2006
4. "Update on Management and Treatment of Chronic Heart Failure"  
Internal Medicine Grand Rounds, Baylor College of Medicine  
Houston, TX; September 4, 2008
5. "Diabetes and Heart Failure: The Management of the Patient with Diabetes and Heart Failure"  
Cardiology Grand Rounds, Albert Einstein College of Medicine, Montefiore Medical Center  
New York, NY; October 14, 2008
6. "Diabetes and Heart Failure: Impact of Glucose Control on Outcomes"  
Cardiology Research Seminar; UCSF General Hospital.  
San Francisco, CA; June 30, 2009
7. "Diabetes and Heart Failure: What do we really know?"  
Cardiology Grand Rounds, MD Anderson Hospital  
Houston, TX; January 20, 2010
8. "Diabetes and Heart Failure: What Do We Really Know?"  
ACC.10: 59<sup>th</sup> Annual Scientific Session  
Atlanta, GA; March 16, 2010
9. "Potential Role of Exenatide and Incretin-Based Therapies in Prevention and Treatment of Heart Failure"  
Amylin Clinical Cardiology Advisory Board Meeting  
Boston, MA; October 20, 2010
10. "Potential Role of Exenatide and Incretin-Based Therapies in Prevention and Treatment of Cardiovascular Disease"  
Amylin Clinical Cardiology Advisory Board Meeting  
Boston, MA; October 20, 2010
11. "Diabetes, Acute Coronary Syndromes, and the Potential Role of Incretin Based Therapy"  
ELIXA Investigator Meeting  
Phoenix, AZ; Jan 8, 2011
12. "Diabetes and Heart Failure: Challenges in Current Therapy and Future Directions"  
Cardiology Grand Rounds, University of Texas Health Science Center  
Houston, TX; February 17, 2011

13. "Diabetes, Acute Coronary Syndromes, and the Potential Role of Incretin Based Therapy"  
ELIXA Investigator Meeting  
Chicago, IL; August 6, 2011
14. "The Cardiovascular Effects of Insulin and GLP-Ras as an Alternative: Clinical Evidence and Illustrative Case Discussion"  
Cardiometabolic Health Congress  
Boston, MA; October 19, 2011
15. "Potential Role of GLP-1 Receptor Agonists in the Prevention and Treatment of Heart Failure"  
Amylin Clinical Cardiology Advisory Board Meeting  
Orlando, FL; November 9, 2011
16. "The Best Treatment for Heart Failure is Prevention: The Patient with Diabetes"  
American Heart Association: Scientific Sessions 2011  
Orlando, FL; November 13, 2011
17. "Controversies in Treatment of Comorbidities in Heart Failure: Paradoxes and Challenges in Treatment Diabetes and Heart Failure" ACC.12 Scientific Sessions  
Chicago, IL; March 2012
18. "Diabetes and Cardiovascular Disease"  
Core Curriculum: Preventive Cardiology  
ACC.12 Scientific Sessions  
Chicago, IL; March 2012
19. "The Latest in Heart Failure with Preserved Ejection Fraction: Case Presentation"  
ACC.12 Scientific Sessions  
Chicago, IL; March 2012
20. "The Landscape of Cardiovascular Research on Antihyperglycemic Agents"  
ELIXA National Coordinator's Meeting  
Chicago, IL; March 27, 2012
21. "The Arranged Marriage of Diabetologists and Cardiologists: Can GLP-1 Agonists Help Us?"  
Endocrine Grand Rounds, Baylor College of Medicine  
Houston, TX; April 12, 2012
22. "Diabetes, Acute Coronary Syndromes, and the Potential Role of Incretin Based Therapy"  
ELIXA Investigator Meeting

Miami, FL; May 4, 2012

23. "HbA1C and Heart Failure: Targets for Diabetes in Heart Failure"  
16<sup>th</sup> Annual Scientific Heart Failure Society of America Meeting  
Seattle, WA; September 12, 2012
24. "Update in Diabetes and Cardiovascular Disease"  
Cardiology Grand Rounds, MD Anderson  
Houston, TX; December 19, 2012
25. "Tough Patients, Tough Decisions for Revascularization in SIHD: Diabetics: What Do I Do Now?"  
ACC.13 Scientific Sessions  
San Francisco, CA; Mar 10, 2013
26. "Diabetes and Cardiovascular Disease"  
Core Curriculum: Preventive Cardiology  
ACC.13 Scientific Sessions  
San Francisco, CA; Mar 10, 2013
27. "Joint Epidemics of Diabetes and Heart Failure"  
AHA Scientific Sessions 2013  
Dallas, TX; November 19, 2013
28. "Chagas Cardiomyopathy: The Hidden Endemic?"  
ACC.14 Scientific Session  
Washington, DC; March 30, 2014
29. "Metabolic Syndrome in Heart Failure: How to Prevent and How to Treat"  
ACC.2014  
Washington, DC; March 31, 2014
30. "Hypertension and Heart Failure"  
ACC.2015  
San Diego, CA; March 16, 2015
31. "Obesity Paradox in Heart Failure is a Fact of Life"  
ACC.2016  
Chicago, IL; April 3, 2016
32. "Heart Failure, Hypertension, and Obesity"  
ACC.2016  
Chicago, IL, April 4, 2016
33. "Galectin-3 & Adverse Cardiovascular Outcomes in Asymptomatic Individuals in the Atherosclerosis Risk in Communities (ARIC) study



AHA Scientific Session 2016  
New Orleans, LA; Nov. 13, 2016

34. "Metabolic Syndrome and Cardiovascular Risk: Impact on Cardiovascular Structure and Inflammation"  
AHA Scientific Session 2016  
New Orleans, LA; Nov. 13, 2016
35. "Stage A: Prevention, Targeting Heart Failure Risk Factors"  
AHA Scientific Session 2016  
New Orleans, LA; Nov. 13, 2016
36. "Diabetes and Heart Failure: The Current Landscape"  
MD Anderson Internal Medicine Grand Rounds  
Houston, Tx; Aug. 11, 2017
37. "Diabetes Medications: Old and New"  
2017 Heart Failure Society Annual Scientific Sessions  
Dallas, TX; Sept. 17, 2017
38. "The Cardiologist Role in Minimizing CV Risk in Patients with Type 2 Diabetes"  
PriMed CME  
Los Angeles, CA; October 5, 2017  
New York, NY; 11/15/2017  
Anaheim, CA; May 29, 2018  
Rosemont, IL; October 10, 2018
39. "Diabetes and Heart Failure: Past Connections and Future Directions:  
2017 American Heart Association Scientific Sessions  
Anaheim, CA; Nov. 12, 2017
40. "Decreasing Cardiovascular Risk with Antihyperglycemic Agents in Patients with Type 2 Diabetes"  
PriMed CME  
Anaheim, CA; May 30, 2018  
Indianapolis, IN; September 18, 2018
41. "Metformin, Sulfonylureas, and Insulin: The Good, the Bad, the Ugly"  
ACC.2018  
Orlando, FL; March 12, 2018
42. "Diabetes and Cardiovascular Disease"  
Diabetes for the Primary Care Provider  
Texas Heart Institute  
Houston, TX; October 21, 2018

43. "Decreasing Cardiovascular Risk with Antihyperglycemic Agents in Patients with T2DM"  
 PriMed CME  
 Rosemont, IL; October 10, 2018  
 New York, NY; Nov 7, 2018
44. "Diabetes and Cardiovascular Disease"  
 Diabetes for the Primary Care Provider  
 Texas Heart Institute  
 Houston, TX; October 21, 2018
45. "The Changing Landscape of CV Risk Reduction in T2DM"  
 MD Anderson Cardiology Grand Rounds  
 Houston, Tx; Dec. 12, 2018
46. "Reducing Cardiovascular Risk in Women with T2DM: New Data & Brand New Guidelines: We are Finally Finding the Sweet Spot"  
 9<sup>th</sup> Annual Heart & Vascular Symposium  
 Texas Heart Institute  
 Houston, Tx; January 26, 2019
47. ACC Co-Chair for Session: "The Intersection of Heart Failure and Diabetes." ACC Scientific Session 2019. March 16, 2019.

## **International**

1. "Diabetes and Heart Failure: What are the Management Options?"  
 European Society of Cardiology (ESC) Congress 2013  
 Amsterdam, NL; September 2013

## **D.2. Letters to the Editor**

1. McGuire DK, Aguilar D. Letter regarding article, "Effect of torcetrapib on glucose, insulin, and hemoglobin A1c in subjects in the investigation of lipid level management to understand its impact in atherosclerotic events (ILLUMINATE) trial". *Circulation* 2012; 125(9):e427
2. Pfeffer MA, Jhund P, Aguilar D. Letter regarding article, "Changes in Diabetes-Related Complications in the United States, 1990–2010." *NEJM* 2014; 371(3):285.

## **D.3. Other**

1. Diabetes and Cardiovascular Disease: ACCEL Interview). (<http://www.youtube.com/watch?v=yPyHCqtrIU>). May 2012; Medical educational interview also available on educational CD series published by the ACC.

2. Presentation from ESC highlighted in MD Conference Express Issue; Peer-reviewed highlights from European Society of Cardiology (ESC) Congress 2013.
3. Presentation from AHA Scientific Session 2013 highlighted in MD Conference Express Issue; Peer-reviewed highlights from American Heart Association 2013.
4. Knowledge to Practice Current MD Cardiology. Online 1-hour web-based learning module for clinicians on “Diabetes and Heart Failure.” Online 9/2018